Direct oral anticoagulants (DOACs) have become entrenched as the dominant anticoagulant over last decade for patients with venous thrombosis and atrial fibrillation.1 Compared to warfarin, bleeding risk is similar or lower on DOACs but clinically relevant still a risk, especially impaired organ function.2